Recommended Dosing and Duration for Nintedanib and Pirfenidone in IPF
For nintedanib, start at 150 mg twice daily with food; reduce to 100 mg twice daily if not tolerated. For pirfenidone, titrate over 14 days to the target dose of 801 mg three times daily (2,403 mg/day) with food. Both medications should be continued indefinitely as long-term therapy unless disease progression, intolerable adverse effects, or other contraindications develop. 1, 2
Nintedanib Dosing
Standard Regimen
- Target dose: 150 mg twice daily (300 mg/day total)
- Administration: Take with food at approximately the same times each day
- Dose reduction: If gastrointestinal side effects (particularly diarrhea) or other adverse events occur, reduce to 100 mg twice daily 3
Key Considerations
The 150 mg twice daily dose was established in the INPULSIS trials and showed significant slowing of FVC decline compared to placebo (difference of 125.2 ml annually) 1. No titration period is required—patients can start directly at the full dose. However, diarrhea is the most common adverse effect, occurring frequently enough that dose reduction is needed in approximately 59% of patients in real-world practice 4.
Pirfenidone Dosing
Titration Schedule (14 days)
- Days 1-7: 267 mg three times daily (801 mg/day)
- Days 8-14: 534 mg three times daily (1,602 mg/day)
- Day 15 onward: 801 mg three times daily (2,403 mg/day) 2
Administration Details
- Take with food at the same time each day to reduce gastrointestinal side effects
- Never take 2 doses at once to make up for a missed dose
- Maximum: 3 doses per day; do not exceed 2,403 mg/day 2
Dose Modifications
If patients experience significant adverse reactions (gastrointestinal symptoms, photosensitivity, rash), consider temporary dose reduction or interruption:
- Interruption <14 days: Resume previous dose
- Interruption ≥14 days: Re-initiate with full 14-day titration schedule 2
For liver enzyme elevations:
- ALT/AST >3-5× ULN without symptoms: May maintain, reduce, or interrupt dose with close monitoring
- ALT/AST >3-5× ULN with symptoms or hyperbilirubinemia: Permanently discontinue
- ALT/AST >5× ULN: Permanently discontinue 2
Treatment Duration
Both medications are intended for continuous, long-term use. The evidence does not support a defined treatment endpoint or maximum duration 1. Treatment should continue indefinitely unless:
- Disease progression despite therapy (consider switching or adding alternative antifibrotic)
- Intolerable adverse effects despite dose reduction
- Development of contraindications
- Patient preference to discontinue
- Lung transplantation
The pivotal trials followed patients for 52 weeks, but real-world data shows median treatment durations of 12.1 months for nintedanib and 27.6 months for pirfenidone, with discontinuation often driven by tolerability rather than lack of efficacy 5.
Important Tolerability Differences
Nintedanib causes more frequent dose reductions (59.3% vs 16.9% for pirfenidone) primarily due to diarrhea, but dose reduction does not appear to compromise efficacy 4. The gastrointestinal adverse event rate is approximately 70% when combined with pirfenidone versus 53% for nintedanib alone 6.
Pirfenidone requires photosensitivity precautions (sunscreen, protective clothing, avoid sun exposure) and has lower overall adverse event rates (56.4%) compared to nintedanib (69.7%) in real-world settings 7. Photosensitivity, nausea, and anorexia are the most characteristic side effects 1.
Drug Interaction Adjustments for Pirfenidone
- Strong CYP1A2 inhibitors (fluvoxamine): Reduce to 267 mg three times daily (801 mg/day) or discontinue fluvoxamine 2
- Moderate CYP1A2 inhibitors (ciprofloxacin 750 mg twice daily): Reduce to 534 mg three times daily (1,602 mg/day) 2
Monitoring Requirements
Before initiating pirfenidone: Conduct liver function tests (ALT, AST, bilirubin) 2
During treatment with either medication: Monitor liver enzymes periodically, particularly in the first months of therapy, and assess for adverse effects at each clinical encounter.